A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy

NCT07623187 | Not Yet Recruiting Phase 2 DMC FDA Drug

• 1 other identifier: CLIN-60340-450
• Study Type: interventional
• Target: 450
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to find out how well the study drug IPN60340 works to treat participants with acute myeloid leukemia. Acute myeloid leukemia is a rare blood cancer that grows quickly. This study's main aim is to compare the percentage of participants who reach complete remission within the first 6 months of treatment between the 2 study arms (study drug and standard medicines compared to placebo and standard medicines). In this study all participants will receive azacitidine and venetoclax plus either the study drug IPN60340 or placebo. Venetoclax will be given as a tablet by mouth once each day in 28-day cycles. Azacitidine will be given by injection under the skin (subcutaneously) or through the veins (intravenously) daily for the first 7 days of each 28-day cycle. IPN60340 or placebo (depending on which arm of the study the participant is assigned to) will be given through the veins (intravenously) on day 1 of each 28-day cycle. There will be 4 periods in this study:

• A screening period (up to 28 days) to assess whether the participant can take part requiring at least 1 visit to the study center.
• A treatment period where all eligible participants will receive azacitidine and venetoclax plus either the study drug IPN60340 or placebo. The study requires 8 visits for the first month followed by 1 visit every month until unacceptable toxicity, disease progression, the start of new cancer treatment, or study closure, whichever is first.
• A safety follow-up period (at 28 days (±3 days) after the last dose of study medicine) to assess safety after participants have finished treatment.
• A long-term follow-up period where participants' health will be monitored using a telephone call or clinic visit every 12 weeks until the end of study. Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), bone marrow aspirates (sampling of the liquid part of the bone marrow). Some participants will also undergo pregnancy testing. Participants in the Phase 3 portion of the study will also be asked to fill in questionnaires. The time each participant will be in this study will vary based on how well the medicine works to treat the participant's AML. Azacitidine and venetoclax plus either IPN60340 or placebo will be provided to participants who tolerate it for as long as their disease does not progress. Participants may withdraw consent to participate at any time.

Conditions

Acute Myeloid Leukaemia (AML); Acute Myeloid Leukaemia

Outcome Measures

Primary Outcomes (1)

• (Phase 2b and Phase 3) Percentage of participants with Complete Remission (CR)

  Complete remission (CR) as defined according to ELN 2022 criteria

  From randomization to end of Cycle 6 (approximately 6 months)

Secondary Outcomes (17)

• (Phase 2b) Overall Survival (OS)

  From randomization until end of study (up to approximately 6 years)

• (Phase 2b) Duration of Complete Remission (DoCR)

  From first documented CR until end of study (up to approximately 6 years)

• (Phase 2b) Event-Free Survival (EFS)

  From randomization to end of study (up to 6 years)

• (Phase 2b) Composite Complete Remission Rate (CRc)

  From randomization to end of Cycle 6 (approximately 6 months)

• (Phase 2b) Complete Remission with Minimal Residual Disease Negative (CR MRD-negative)

  From randomization to end of cycle 6 (6 months)

Study Arms (2)

IPN60340 in combination azacitidine plus venetoclax (IAV)

EXPERIMENTAL

In phase 2b, approximately 90 participants will be randomized in a 1:1 ratio to IAV. In phase 3, approximately 450 participants will be randomized in a 1:1 ratio to IAV. Regardless of the phase, participants will be randomized prior to dosing. Participants who are enrolled in phase 2b of the study will not be allowed to enroll in phase 3 of the study.

Biological: IPN60340 + azacitidine + venetoclax

Placebo in combination azacitidine plus venetoclax (PAV)

ACTIVE COMPARATOR

In phase 2b, approximately 90 participants will be randomized in a 1:1 ratio to PAV. In phase 3, approximately 450 participants will be randomized in a 1:1 ratio to PAV. Regardless of the phase, participants will be randomized prior to dosing. Participants who are enrolled in phase 2b of the study will not be allowed to enroll in phase 3 of the study.

Drug: Placebo + azacitidine + venetoclax

Interventions

IPN60340 + azacitidine + venetoclax BIOLOGICAL

: IPN60340 + azacitidine + venetoclax Participants will receive: * IPN60340 per protocol by intravenous (IV) infusion in each 28-day treatment cycle * azacitidine by subcutaneous (SC) or IV daily for the first week in each 28-day treatment cycle * venetoclax orally daily every day of each 28-day treatment cycle

Also known as: ICT01

IPN60340 in combination azacitidine plus venetoclax (IAV)

Placebo + azacitidine + venetoclax DRUG

Participants will receive: * Placebo per protocol by intravenous (IV) infusion in each 28-day treatment cycle * azacitidine by subcutaneous (SC) or IV daily for the first week in each 28-day treatment cycle * venetoclax orally daily every day of each 28-day treatment cycle

Also known as: NaCl

Placebo in combination azacitidine plus venetoclax (PAV)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must be 18 years of age or older, at the time of signing the informed consent.
• Have newly diagnosed AML, as per WHO 2022 criteria.
• Eastern Cooperative Oncology Group (ECOG) performance status of 1 to 2 for participants ≥75 years of age, or 1 to 3 for participants \<75 years of age
• Participants must be considered ineligible for intensive chemotherapy, due to age or comorbidities,
• Adequate organ function as indicated in the protocol
• Contraceptive use by participant or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.
• Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

You may not qualify if:

• Participants are excluded from the study if any of the following criteria apply:
• Current diagnosis of:
• I. Acute promyelocytic leukemia (APL) II. Active or uncontrolled central nervous system (CNS) leukemia III. Any γ9δ2TC neoplasm
• History of myeloproliferative neoplasms (MPN) including primary myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia, or MDS/MPN as per WHO 2022 or treatment-related AML
• History of other malignancy within the last 2 years.
• Rapidly progressing disease in the opinion of the clinical investigator which may preclude treatment in this study.
• History of clinically significant or uncontrolled cardiac disorders, within 6 months prior to Cycle 1 Day 1 (C1D1)
• White blood cell (WBC) count \>25 × 10\^9/L . Cytoreduction can be used before C1D1 and beyond as needed to keep WBC \< 25 × 10\^9.
• Participants with severe hepatic impairment, e.g., Child-Pugh C, are excluded.
• Major surgery within 4 weeks prior to C1D1 or planned during the foreseeable duration of the study.
• Any gastrointestinal disorder or malabsorption syndrome that may impair absorption of venetoclax
• Uncontrolled or severe bacterial, fungal, viral, and/or parasitic infections treated with therapeutic oral or intravenous anti-infective agents. Prophylactic antimicrobials are allowed.
• Uncontrolled human immunodeficiency virus (HIV) disease will be excluded. Participants on anti-retroviral therapy should be included as long as their disease is under control, taking precautions to modify their highly active antiretroviral therapy (HAART) regimen to minimize drug interactions.
• Presence of hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to randomization.
• NOTE: Participants with known positive HBsAb may be randomized provided they are hepatitis B-vaccinated and have negative HBsAg and HBcAb.

Sponsors & Collaborators

• Ipsen: lead

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Interventions

Azacitidine; venetoclax

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Aza Compounds; Organic Chemicals; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Ribonucleosides

Central Study Contacts

Ipsen Clinical Study Enquiries

CONTACT

See email; clinical.trials@ipsen.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 28, 2026
• First Posted: June 3, 2026
• Study Start (Estimated): November 1, 2026
• Primary Completion (Estimated): May 31, 2031
• Study Completion (Estimated): May 31, 2032
• Last Updated: June 3, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share
• Time Frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
• Access Criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).